Introduction
============

Motile cilia and flagella are complex microtubule-based organelles critical for embryonic development and organ functions ([@bib68]; [@bib65]; [@bib43]; [@bib72]). Ciliary motility is generated by the coordinated activities of both the axonemal outer dynein arms (ODAs) and inner dynein arms (IDAs), which are regulated in a precise spatial and temporal manner ([@bib3]; [@bib29]; [@bib35]; [@bib47]). Although the ODAs generate the main force for control of ciliary beat frequency, the IDAs mainly contribute to control of the size and shape of the ciliary bend, parameters referred to as waveform ([@bib6]; [@bib35]). Failure in proper coordination and regulation of the dyneins results in abnormal ciliary motility, which is implicated in a wide range of human diseases known as ciliopathies ([@bib49]; [@bib24]; [@bib10]; [@bib25]; [@bib55]). However, we have little understanding of the mechanisms that coordinate the activity among the different ciliary dynein arms or that regulate the activity of each dynein subform ([@bib29]; [@bib5]; [@bib48]; [@bib51]).

Theoretical and experimental analyses have indicated the oscillatory movement of cilia is, in part, an inherent property of the dynein motors ([@bib83]; [@bib70]) and regulation by a mechanical feedback mechanism, in which axonemal curvature or distortion regulates dynein activity ([@bib19]; [@bib4], [@bib5]; [@bib52]; [@bib18]; [@bib47]). However, effective motility of cilia also requires precise control of beat frequency and waveform, through regulation of the ODA and IDA, respectively. At least five conserved, key axonemal complexes have been identified that regulate normal ciliary motility. They include the central pair (CP) apparatus, radial spokes (RSs), the nexin--dynein regulatory complex (N-DRC; [@bib21]), the calmodulin- and spoke-associated complex (CSC; [@bib12]; [@bib22]), and the two-headed IDA called I1 dynein, also known as dynein f ([@bib61]; [@bib63]). The regulatory mechanisms are thought to involve structural and chemical signals that begin in the CP and are then transmitted to the outer doublet microtubules (DMTs) by the RSs ([Fig. 1, A and B](#fig1){ref-type="fig"}; [@bib74]). Although the composition and structure of the RSs have recently been revealed ([@bib60]; [@bib45]), how the RSs transmit signals to the outer DMTs is not understood.

![**Schematic model of motility regulation in *C. reinhardtii* axonemes.** (A and B) Models depicting mechanical/chemical signaling pathways (dotted red arrows) in *C. reinhardtii* axonemes. Transverse (A) and longitudinal (B) sections are shown. Based on genetic and pharmacological experiments, signals are transmitted from the CP, through the RS1 to I1 dynein, and through RS2 to the CSC and N-DRC. Signals are also thought to be transmitted from I1 dynein and N-DRC to ODAs through OIDLs (blue lines in B). The question addressed here is how signals are transmitted to I1 dynein (question marks in A and B).](JCB_201211048_Fig1){#fig1}

The CSC, which is required for regulation of dynein and for calcium regulation of motility ([@bib12]; [@bib22]), is associated with RS2 and the N-DRC in the distal region of the axonemal 96-nm repeat structure ([@bib15]; [@bib21]; [@bib44]). Thus, the N-DRC and CSC are in perfect position to relay structural and/or chemical signals initiated in the CP and transmitted by the RSs to the dynein motors. However, despite recent detailed structural analyses showing physical connections between the N-DRC and CSC ([@bib22]) and the N-DRC and dynein motors ([@bib7]; [@bib21]), the mechanisms for regulation and signal transduction remain a mystery.

In the proximal part of the axonemal 96-nm repeat, the I1 dynein is the corresponding key regulator of dynein-driven microtubule sliding, relaying signals that are required for normal ciliary waveform ([@bib79]; [@bib78]). I1 dynein is the only two-headed IDA, and the functional mechanism involves changes in phosphorylation of its regulatory intermediate chain (IC) IC138 by axonemal kinases and phosphatases ([@bib16]; [@bib13]) and is also regulated by the CP and RS ([@bib74]). Based on additional genetic analysis ([@bib64]) and measurement of microtubule sliding ([@bib73]; [@bib71]; [@bib2]; [@bib77]), the CP/RS structures also appear to regulate the ODAs, possibly mediated by I1 dynein ([@bib32]). Consistent with this idea, recent cryo--electron tomography (cryo-ET) studies have revealed intriguing structural links between I1 dynein and the ODAs ([@bib54]; [@bib7], [@bib9]; [@bib23]), possibly to coordinate activities between these dyneins. However, neither the proteins nor the functional roles of these linkers have been elucidated, nor have regulatory mechanisms that coordinate various axonemal dyneins been identified. One idea is that I1 dynein predominantly plays a regulatory role, like the N-DRC, controlling the activity of other dyneins ([@bib38]; [@bib2]; [@bib77]; [@bib23]). However, the mechanism of transmission of signals from the RSs to I1 dynein and regulation of I1 dynein is not understood.

To further investigate the mechanism for how I1 dynein is regulated, we analyzed two *Chlamydomonas reinhardtii* motility mutants, *mia1* and *mia2*. The *mia* mutants were identified in genetic screens for cells with defects in axonemal dynein regulation ([@bib34]). The mutants fail to perform normal phototaxis and display abnormal phosphorylation of IC138, indicative of a defect in regulation of I1 dynein and control of ciliary waveform ([@bib2]; [@bib78]). Here, we report that the gene products of *mia1* and *mia2* are the conserved coiled-coil proteins, FAP100 and FAP73, respectively, that form a tight complex in the axoneme, which we named the modifier of inner arms (MIA) complex. Cryo-ET indicates that the MIA complex is localized to every 96-nm axonemal repeat just distal to the I1 dynein IC/light chain (LC) complex and proximal to the N-DRC. Biochemical data demonstrate that the MIA complex interacts with I1 dynein components, and structural data suggest that I1 dynein is structurally more flexible in the *mia* mutants. The *mia* mutants also display reduced ciliary beat frequencies indicative of defects in regulation of the ODAs. These results are consistent with the idea that the MIA complex functions in a regulatory pathway that controls the activities of I1 dynein and possibly of the ODAs.

Results
=======

The *MIA1* gene encodes the coiled-coil protein FAP100
------------------------------------------------------

While searching for *C. reinhardtii* IDA-deficient mutants from our UV-mutagenized library ([@bib30]), we isolated three motility mutants, 317, 623, and 834, which showed slightly jerky, slow-swimming phenotypes, reduced flagellar beat frequencies, and defective phototaxis. The mutations mapped to linkage group II/chromosome 2 near the previously mapped location for the *mia1* mutant ([@bib34]). Of the candidate genes in this region, *FAP100* was of particular interest because it is highly conserved in organisms with motile cilia, and its predicted mass (65.2 kD with an isoelectric point of 5.37) is consistent with that previously reported for a protein missing in *mia1* ([@bib34]). Sequence analysis revealed mutations in the *FAP100* gene for all three strains as well as the original *mia1*: strain 317 has a T to A substitution, which creates a premature stop at codon 127; strain 623 has a one-base deletion in codon 534 (GTG to GG), resulting in a frame shift mutation; and strain 834 has a two-base (GG to AA) substitution, which alters the 5′ splice site of exon 2 ([Fig. 2, A and B](#fig2){ref-type="fig"}). The original *mia1* mutant ([@bib34]) has the ∼560-bp "Bill" transposon ([@bib33]) inserted in the first exon of *FAP100*, resulting in failure of expression of this protein ([Fig. 3 A](#fig3){ref-type="fig"}). Because 317, 623, and 834 are alleles of *mia1*, we renamed the original *mia1* to *mia1-1*, 317 to *mia1-2*, 623 to *mia1-3*, and 834 to *mia1-4*. We made an antibody against the FAP100 protein ([Fig. S1](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp1}), and immunoblotting revealed that FAP100 is missing from axonemes from all three of these strains as well as the original *mia1-1* ([Fig. 3 A](#fig3){ref-type="fig"}). Using the wild-type *FAP100* genomic fragment with a triple HA (3×HA) tag at the C terminus of the coding region, we rescued the *mia1* phenotype. The rescued strain, *mia1R*, had nearly wild-type motility and phototaxis (unpublished data). Furthermore, immunoblot analysis revealed that FAP100-HA is assembled in the axonemes from *mia1R* ([Fig. 3 B](#fig3){ref-type="fig"}). The data definitively reveal that *MIA1* encodes FAP100.

![**The *MIA1* and *MIA2* genes in *C. reinhardtii* encode conserved coiled-coil proteins.** (A) The genomic structure of the *MIA1* and *MIA2* genes, showing untranslated regions in blue, exons in red, and introns as black lines. The mutations in the *mia1* alleles and *mia2* are indicated. (B) Sequence analyses of the *mia* mutants (*mia1-2*/*317*, *mia1-3*/*623*, *mia1-4*/*834*, and *mia2*) reveal the consequences resulting from the indicated mutations. Coloring indicates DNA bases (blue, cytosine; red, thymine; green, adenine; black, guanine). Asterisks indicate mutations sites.](JCB_201211048_Fig2){#fig2}

![**The Mia1 and Mia2 proteins form the MIA complex.** (A) Anti-FAP100 and -FAP73 antibodies detect bands in wild-type axonemes. Both bands are missing or greatly reduced in *mia1*, whereas only the FAP73 band is missing in *mia2*. CBB staining of tubulin from each sample is shown as a loading control. (B) Axonemes from HA-tagged rescued strains (*mia1R* and *mia2R*) assemble FAP100 (top) and FAP73 (bottom). The expressed proteins have slower migration as a result of the expression of the 3×HA tags. (C) Immunoprecipitations from *mia1R* extracts using the anti-HA antibody pull down an ∼76-kD protein (FAP100-HA) and an ∼35-kD protein (FAP73; both indicated by red arrows). Plus and minus signs indicate addition of beads with or without the anti-HA antibody. Immunoblots using the specific antibodies also show that these proteins were precipitated only in the *mia1R* extracts. (D) The Mia1p (FAP100; top) and Mia2p (FAP73; bottom) domain structures were predicted using the SMART and COILS programs. Both proteins show a high probability of forming coiled-coil domains in the middle part of the protein. The color coding in the structure prediction by SMART analysis: green, regions having a high probability of forming coiled-coil structure; pink, regions of low complexity; gray, areas with no detectable domains. The window width in the structure prediction by COILS version 2.2: green, 14 residues; blue, 21 residues; red, 28 residues. wt, wild type.](JCB_201211048_Fig3){#fig3}

FAP100/Mia1p interacts with the coiled-coil protein FAP73/Mia2p to form the MIA complex
---------------------------------------------------------------------------------------

To identify FAP100-interacting proteins, we immunoprecipitated FAP100-HA from high salt extracts derived from *mia1R* axonemes using anti-HA antibodies ([Fig. 3 C](#fig3){ref-type="fig"}). Comparison between precipitates from *mia1R* and wild type, which does not express HA-tagged FAP100, clearly identified an ∼76-kD protein and an ∼35-kD protein that were exclusively pulled down in precipitates from *mia1R* extracts. Mass spectrometry (MS) analysis revealed the 76-kD band to be FAP100-HA and the 35-kD band to be FAP73. Both are coiled-coil proteins ([Fig. 3 D](#fig3){ref-type="fig"}) conserved in organisms with motile cilia and flagella. The molecular mass of FAP73 (35.6 kD with an isoelectric point of 5.65) is consistent with that determined for a protein greatly reduced in *mia1* axonemes ([@bib34]).

FAP73 maps to linkage group XVIII/chromosome 16 near the map position for the *mia2* mutant ([@bib34]). Like *mia1*, *mia2* displays highly phosphorylated forms of IC138 in the axoneme ([@bib34]). In *mia2*, the *FAP73* gene has a one-base substitution (C to T), resulting in a premature stop at codon 105 ([Fig. 2, A and B](#fig2){ref-type="fig"}). An antibody to FAP73 (Fig. S1) confirmed that FAP73 is missing from *mia2* axonemes ([Figs. 3 A](#fig3){ref-type="fig"} and [4 A](#fig4){ref-type="fig"}), demonstrating that *mia2* is a null allele. We rescued the phototaxis and motility defects (not depicted) in *mia2* with a HA-tagged FAP73 protein (*mia2R*; [Fig. 3 B](#fig3){ref-type="fig"}). The data definitively reveal that *MIA2* encodes FAP73.

Although FAP100 and FAP73 are both absent or greatly reduced from *mia1* axonemes, FAP100 is present in *mia2* axonemes ([Figs. 3 A](#fig3){ref-type="fig"} and [4 A](#fig4){ref-type="fig"}). Based on the coimmunoprecipitation and other biochemical data, FAP100 and FAP73 form an axonemal complex, which we call the MIA complex after the names of original *C. reinhardtii* mutants. The stoichiometry of FAP100 and FAP73 in the MIA complex was estimated to be 1:1.83--2.89 from exponentially modified protein abundance index scores in our MS analysis and 1:2.53 from numbers of peptides per molecular weight observed in the *C. reinhardtii* proteome ([@bib58]).

The MIA complex localizes to the outer DMTs
-------------------------------------------

To determine where the MIA complex localizes, we performed immunoblotting experiments using mutants lacking specific axonemal structures ([Fig. 4 A](#fig4){ref-type="fig"}). The MIA complex was present in axonemes defective in the CP (*pf18*), RS (*pf14* and *pf17*), ODA (*oda1*), I1 dynein (*ida1*), single-headed inner arms (*ida5*), the N-DRC (*pf3*), beak structures (*mbo1* and *mbo2*), and the protein phosphatase PP2A (*pf4*). Double mutants *oda1 × ida1*, *oda1 × ida2*, and *ida1 × ida5* also had normal amounts of FAP100 and FAP73. Thus, the MIA complex is located on the outer DMTs.

![**FAP100 and FAP73 assemble in various motility mutants and the *mia* mutants contain ODAs and IDAs.** (A) Both FAP100 and FAP73 assemble in mutant axonemes that are missing the ODAs (*oda1*), I1 dynein (*ida1*), the single-headed IDAs a, c, d, and e (*ida5*), the N-DRC (*pf3*), the PP2A phosphatase (*pf4*), the RSs (*pf14 and pf17*), the CP (*pf18*), and the beaklike structures (*mbo1* and *mbo2*). The proteins are also present in double mutants (*oda1 × ida1*, *oda1* × *ida2*, and *ida1* × *ida5*). (B) Immunoblots of subunits of the ODAs (IC69), I1 dynein (IC140 and IC97), the single-headed IDAs (actin and p28), and the RSs (RSP1) indicate these axonemal structures are apparently normal in both *mia1* and *mia2*. The dynein subunits were detected on a single gel and blot, and RSP1 was detected on a second gel and blot. Ponceau staining of tubulin is shown as a loading control for each gel. (C) Silver-stained 3--5% urea gel of isolated axonemes demonstrates that dynein HC composition appears unaltered in *mia* mutants relative to wild type. Three lanes are from the same gel. The predicted molecular mass of I1 dynein HCs is the expected value: dynein HCs migrate significantly more slowly than the 250-kD molecular mass marker, which is shown well below the region of the gel shown. wt, wild type.](JCB_201211048_Fig4){#fig4}

Given the slow-swimming phenotype of *mia* strains, we analyzed *mia* mutant axonemes for the presence of other notable axonemal structures. Biochemical analyses indicate that *mia* mutant axonemes have normal amounts of outer arms (IC69), single-headed inner arms (p28 and actin), RS (RSP1; [Fig. 4 B](#fig4){ref-type="fig"}), and a normal dynein heavy chain (HC) profile ([Fig. 4 C](#fig4){ref-type="fig"}). In addition, assembly of I1 dynein (HCs, IC140, and IC97) in *mia* mutants appeared relatively normal ([Fig. 4, B and C](#fig4){ref-type="fig"}), although there are slight differences from culture to culture and allele to allele. Furthermore, the *mia* mutants manifest a highly phosphorylated IC138 ([Fig. 5 A](#fig5){ref-type="fig"}) consistent with a previous study ([@bib34]), suggesting a defect in I1 dynein regulation. However, immunoblots indicate normal levels of signaling components (CK1, PP1, and PP2A; [Fig. 5 B](#fig5){ref-type="fig"}) important in the CP--RS pathway that regulates phosphorylation of IC138 (e.g., [@bib16]; [@bib13]). Thus, failure in assembly of the MIA complex does not result in failure of assembly of other axonemal proteins, including the kinases and phosphatases that regulate I1 dynein.

![**The MIA complex functions in the I1 dynein phosphoregulatory pathway and interacts with multiple axonemal proteins.** (A) Untreated flagella (fla), untreated axonemes (axo), and axonemes treated with the kinase inhibitor DRB were probed with the anti-IC138 antibody. In the *mia* untreated axonemes, IC138 migrates in multiple forms in a manner similar to *pf17*. In contrast, wild-type axonemes show a compact IC138 profile. DRB treatment results in a shift in migration of IC138, indicating that these multiple forms of IC138 are caused by phosphorylation. (B) Immunoblot analyses indicate that CK1, PP2A (B and C subunits \[sub\]), and PP1 are assembled normally in the *mia* mutants. (C) Isolated wild-type axonemes treated with or without 5 mM EDC were probed with the FAP100 and FAP73 antibodies. Upon EDC exposure, both Mia proteins form some cross-linked products (red arrowheads), indicating that the MIA complex is in direct contact with multiple axonemal proteins. We could not detect the cross-linked products between I1 dynein subunits and the Mia proteins as solid bands on these blots. Black arrows indicate the un--cross-linked FAP100 and FAP73. Ab, antibody; wt, wild type.](JCB_201211048_Fig5){#fig5}

The MIA complex interacts with I1 dynein in the axoneme
-------------------------------------------------------

To identify proteins that interact with the MIA complex in the axoneme, we used chemical cross-linking with EDC (1-ethyl-3-\[3-dimethylaminopropyl\] carbodiimide hydrochloride) followed by immunoprecipitation and identification by electrospray ionization (ESI)/liquid chromatography/MS/MS. Both FAP100 and FAP73 form cross-linked products in the axoneme upon exposure to EDC ([Fig. 5 C](#fig5){ref-type="fig"}). Using the rescued strains (*mia1R* and *mia2R*) and anti-HA antibodies for immunoprecipitation, I1 dynein HCs α and β and IC138 were precipitated from *mia1R*, and I1 dynein HC-β and IC138 were precipitated from *mia2R* ([Table S1](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp2}), strongly suggesting that the MIA complex physically interacts with IC138 and/or I1 dynein HCs. In addition to I1 dynein components, several other axonemal proteins were identified as potential components of the MIA complex (Table S1). Although the *mia* mutants display altered IC138 phosphorylation, no apparent kinase or phosphatase was precipitated with either FAP100-HA or FAP73-HA.

Cryo-ET reveals that the MIA complex is located distal to the IC/LC complex of I1 dynein, possibly extending across the middle of the 96-nm repeat to the N-DRC
---------------------------------------------------------------------------------------------------------------------------------------------------------------

Immunofluorescence of nucleoflagellar apparatuses from *mia1R* clearly showed that FAP100 is present along the entire length of both cilia, which is the same localization pattern obtained for I1 dynein ([Fig. 6 A](#fig6){ref-type="fig"}; [@bib9]). To definitively determine structural changes and to localize the MIA complex, we used cryo-ET and subtomogram averaging of the 96-nm axonemal repeat to analyze the 3D structures of *mia* axonemes and compare them with pseudo--wild type (pWT) and *pf9-3*/*ida1* ([Videos 1](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp3} and [2](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp4}). Consistent with our EDC cross-linking results ([Fig. 5 C](#fig5){ref-type="fig"} and Table S1), cryotomographic averages of both *mia1* and *mia2* axonemes revealed structural defects in the distal portion of the I1 dynein IC/LC complex and in the structure located between I1 dynein and the N-DRC ([Figs. 6, B and C](#fig6){ref-type="fig"}; and [S2, A--C](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp5}; and [Videos 3](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp6}, [4](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp7}, and [5](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp8}). These structural defects are more severe in *mia1* than in *mia2*, supporting our biochemical results that *mia1* axonemes lack both FAP100 and FAP73, whereas *mia2* lacks only FAP73. Consistent with our biochemical analysis ([Fig. 4, B and C](#fig4){ref-type="fig"}), other structures including the RSs, N-DRC, and the dynein structures appear fully assembled as in the pWT control ([Figs. 6, B and C](#fig6){ref-type="fig"}; and S2, A--C; and Videos 1, 3, and 4).

![**The MIA complex is localized to a unique position in each 96-nm repeat.** (A) Nucleoflagellar apparatuses from *oda1* and *mia1R* × *oda1* were stained with the anti-HA antibody. The HA antibody detects FAP100-HA in both flagella in the *mia1R* × *oda1* strain (fluorescence image on the bottom). Very weak or no signal was detected in *oda1* flagella that do not express the FAP100-HA protein. Both basal bodies and nuclei have some nonspecific staining. (top) Differential interference contrast images show that all cells possess flagella. Arrowheads indicate cis- and trans-flagella, showing that both flagella are staining. (B) Longitudinal tomographic slices of the averaged 96-nm axonemal repeats from DMTs 1--9 of pWT, *mia2*, *mia1*, and *pf9-3/ida1* reveal structural defects in the mutant axonemes. The density of the I1 dynein (red outlines) is completely missing in *pf9-3/ida1* (white outlines) and appears reduced in the *mia* mutants. These defects are more prominent in *mia1* than in *mia2*. The densities of other major axonemal structures, such as the ODAs, single-headed inner dynein arms (IDAs 2--6 and X), and the N-DRC are not significantly changed in the *mia* mutants. (C) 3D isosurface renderings of the averaged 96-nm axonemal repeats from pWT, *mia2*, *mia1*, and *pf9-3/ida1* reveal the structural defects in more detail. Regions that are reduced in the *mia* averages are colored green; the most obvious defects are the distal density of the IC/LC of I1 dynein (orange) and the density between the I1 dynein and the N-DRC (yellow), which is reduced in *mia2*, missing in *mia1*, but fully assembled in pWT and *pf9-3/ida1*. The pWT and *pf9-3/ida1* data were refined from data originally reported by [@bib23]. Proximal is on the left in B and C. Bars: (A) 10 µm; (B) 25 nm.](JCB_201211048_Fig6){#fig6}

Consistent with previous data ([@bib54]; [@bib2]; [@bib23]), axonemes of the *pf9-3/ida1* mutant lack the entire I1 dynein, including the distal portion of the IC/LC complex that is reduced in the *mia* mutants. In contrast, the structure that bridges between the I1 dynein and N-DRC, which is missing or greatly reduced in the *mia* mutants, is present in *pf9-3/ida1* and pWT axonemes ([Figs. 6 C](#fig6){ref-type="fig"} and S2, A--C; and Videos 1, 2, 3, 4, and 5). Therefore, failure in I1 dynein assembly does not alter assembly of the MIA complex.

The MIA complex is important for the stable attachment of I1 dynein to the axoneme
----------------------------------------------------------------------------------

The majority of the I1 dynein density is present in *mia* mutants, but we observed by cryo-ET that the density of the I1 dynein appeared weaker and blurred compared with pWT ([Figs. 6 B](#fig6){ref-type="fig"} and S2, A--C). This blurring was only observed for the I1 dynein and not for other axonemal structures. The blurred density of I1 dynein in the *mia* averages indicates heterogeneity between the averaged axonemal repeats, either because of assembly or positional differences, leading to bad alignment of just the I1 dynein in relation to the other axonemal structures. Classification of all averaged subtomogram volumes concerning presence or absence of the I1 dynein detected only occasional missing of the I1 dynein, mostly in random 96-nm repeats of both *mia* mutants (unpublished data). To test whether the position of I1 dynein is more flexible in *mia* axonemes than in wild type, we calculated local averages of the I1 dynein by masking all other structures during the alignment process. In contrast to the global averages in which the alignment is dominated by the density of the DMTs and other structures in the 96-nm repeat, in the local average of both *mia1* and *mia2*, the density of the I1 dynein appears very similar to the density in pWT, whereas the surrounding axonemal structures are greatly blurred because of alignment errors (unpublished data). This suggests that the I1 dynein density in the *mia* averages is mostly reduced because the position of the I1 dynein is more variable in the *mia* mutants than in pWT, which is consistent with a structural interaction between I1 dynein and the MIA complex.

In addition, doublet-specific averaging revealed an intriguing feature of *mia* mutant axonemes ([Figs. 7 A](#fig7){ref-type="fig"} and [S3](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp9}). DMTs 2--9 assemble all the IDA and ODA structures, and the defects noticeable are the missing densities distal of I1 dynein as described in the previous paragraph. Doublet-specific averages of DMTs 2--9 did not reveal obvious differences between these doublets in regards to the structural defects found in the *mia* mutants (Fig. S3). However, DMT1 of *mia1* and *mia2* axonemes shows additional defects compared with pWT. In wild-type *C. reinhardtii* flagella, DMT1 is known to exhibit unique features compared with DMTs 2--9: (a) the ODAs and the outer--inner dynein linkers (OIDLs) are missing along the entire length of DMT1, (b) in the proximal quarter of the flagellum, the ODAs are substituted by the 1--2 bridge that links DMTs 1 and 2 ([Fig. 7 A](#fig7){ref-type="fig"}; [@bib26]; [@bib8], [@bib9]; [@bib46]), and (c) in the proximal region where the 1--2 bridge is present, the I1 dynein is missing ([@bib9]; [@bib46]). In the *mia* mutants, however, I1 dynein is missing along the entire length of DMT1.

![**The MIA complex affects I1 dynein stability in the axoneme.** (A) I1 dynein is missing along the entire length of DMT1 in the *mia* mutants. Tomographic slices of axonemal average of individual outer DMTs from pWT (top row), *mia2* (middle row), and *mia1* (bottom row). The first two columns show the axonemal repeat of DMT1 in the proximal (left) and distal (middle) regions; the right column depicts the combined average of the axonemal repeats from DMTs 2--9 that do not show obvious structural differences between the proximal and distal regions (for individual DMT averages, see [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp10}). In wild type, I1 dynein is missing from the proximal region of DMT1 (white outlines) but is present in the distal region (red outlines). In contrast, in both *mia* mutants, I1 dynein is missing along the entire length of DMT1 (white outlines). The pWT data were refined from data originally reported by [@bib21] and [@bib46]. Other structures labeled are single-headed inner dynein arms (IDAs 2--6 and X), the N-DRC, and the inner SUB5-6 bridge. Bars, 25 nm. (B) Representative ion-exchange chromatography (Mono Q; GE Healthcare) elution profiles of axonemal dyneins show that I1 dynein levels (black arrows) appear relatively normal in *mia1-2* extracts compared with that of wild-type extracts (left graph), consistent with the immunoblotting results using I1 dynein subunit antibodies ([Fig. 4 B](#fig4){ref-type="fig"}). In contrast, I1 dynein is drastically reduced in the *mia1-2* × *oda6* double mutant (red arrow) compared with the *oda1* single mutant (right graph), suggesting that I1 dynein becomes unstable without both ODAs and the MIA complex. Typical Mono Q elution patterns are shown (A280 protein estimate in arbitrary units is indicated to the right of each scan \[y axis\]; elution time in minutes is shown on the x axis), and at least two experiments were performed for each strain. Elution of dynein complexes began at ∼12 min. (C) Immunoblot analysis of isolated axonemes using the anti-DHC1 (I1 dynein HC-α) and IC97 antibodies confirms the reduction of I1 dynein in *mia* × *oda* double mutants. I1 dynein appears normal to slightly reduced in the single *mia* mutants relative to wild type (wt).](JCB_201211048_Fig7){#fig7}

The results suggested that the MIA complex is located on all outer doublets (Fig. S3). However, one interpretation of the doublet-specific *mia* mutant defect is that I1 dynein assembly and stability are dependent on assembly of both the ODAs and the MIA complex, with the ODAs missing from DMT1. To test this, we used protein fractionation and immunoblots to compare the amount of I1 dynein assembled in axonemes from a *mia1* × *oda6* double mutant (lacking the MIA complex and ODAs) to *oda1* or *oda6* lacking only the ODAs. Chromatographic separation of flagellar dyneins revealed that the amount of I1 dynein is indeed reduced in axonemes from *mia1* × *oda6* compared with that of *oda1* ([Fig. 7 B](#fig7){ref-type="fig"}). In addition, immunoblots using antibodies to the I1 dynein HC and IC97 revealed a similar reduction of I1 dynein in other *mia* × *oda* double mutants ([Fig. 7 C](#fig7){ref-type="fig"}). These results indicate that I1 dynein assembly fails when both the ODA and MIA complex are missing and is dependent on both structures. Among these two stabilizing complexes, the MIA complex seems to be more crucial for stable I1 dynein assembly because, in contrast to the MIA complex, the absence of ODAs alone does not cause increased flexibility of the I1 dynein ([Fig. 7 A](#fig7){ref-type="fig"}, distal portion of DMT1 in pWT).

The MIA complex controls ciliary/flagellar motility through regulation of dynein activity
-----------------------------------------------------------------------------------------

The *mia* mutants were first isolated as slow-swimming, nonphototactic cells ([@bib34]). These are motility phenotypes common to defective I1 dynein assembly or regulation ([@bib57]; [@bib13]; [@bib78]) and that display excessive phosphorylated forms of IC138 ([@bib34]). These observations are consistent with a role for the MIA complex in regulation of I1 dynein. In addition, from our analyses, the *mia* mutants have both swimming speed (∼60 µm/s) and beat frequency (40--50 Hz) defects ([Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp11} and [Table 1](#tbl1){ref-type="table"}) that are more severe than those observed for I1 dynein mutants (swimming velocity: ∼100 µm/s; beat frequency: ∼60 Hz; [Table 1](#tbl1){ref-type="table"}; [@bib20]; [@bib78]), indicating that the MIA complex may regulate multiple dyneins, including direct or indirect regulation of the ODAs.

###### 

Phenotypes of the *mia* mutants

  Mutant              Defect                            Phenotype                                                                 Typical beat frequency
  ------------------- --------------------------------- ------------------------------------------------------------------------- ------------------------
                                                                                                                                  *Hz*
  Wild type           None                              Slightly jerky or smooth, fast swimming                                   60--70
  *mia1-1*            MIA complex                       Slightly jerky, slow swimming                                             40--50
  *mia1-2*                                                                                                                        
  *mia1-3*                                                                                                                        
  *mia1-4*                                                                                                                        
  *mia2*              MIA complex                       Slightly jerky or jerky (some cells), slow swimming                       ∼40
  *mia1-1 × mia2*     MIA complex                       Slightly jerky or jerky (some cells), slow swimming (similar to *mia*)    40--50
  *mia1-1 × bop5-4*   MIA complex; IC138 complex        Slightly jerky or smooth (some cells), slow swimming (similar to *mia*)   40--50
  *mia1-3 × ida1*     MIA complex; I1 dynein            Slightly jerky or smooth (some cells), slow swimming (similar to *mia*)   40--50
  *mia1-2 × ida2*     MIA complex; I1 dynein            Slightly jerky or smooth (some cells), slow swimming (similar to *mia*)   40--50
  *mia1-2 × ida4*     MIA complex; dynein a, c, and d   Nearly nonmotile (more severe than *mia*)                                 \<10
  *mia1-4 × ida4*     MIA complex; dynein a, c, and d   Nearly nonmotile (more severe than *mia*)                                 \<10
  *mia1-1 × ida9*     MIA complex; dynein c             Nonmotile or beat at very low beat frequency (more severe than *mia*)     \<10
  *mia1-2 × oda1*     MIA complex; ODA                  Beat at very low beat frequency (more severe than *mia*)                  10--20
  *mia1-3 × oda2*     MIA complex; ODA                  Beat at very low beat frequency (more severe than *mia*)                  10--20
  *mia1-1 × oda6*     MIA complex; ODA                  Beat at very low beat frequency (more severe than *mia*)                  10--20
  *mia1-1 × pf4*      MIA complex; PP2A phosphatase     Beat at low beat frequency (more severe than *mia*)                       ∼30
  *mia1-1 × pf17*     MIA complex; RS head              Nonmotile (more severe than *mia*)                                        N/A
  *mia2 × bop5-3*     MIA complex; IC138 complex        Slightly jerky or smooth (some cells), slow swimming (similar to *mia*)   40--50
  *mia2 × ida6*       MIA complex; N-DRC; dynein e      Nonmotile or sporadic twitching (more severe than *mia*)                  N/A
  *mia2 × ida9*       MIA complex; dynein c             Nonmotile or beat at very low beat frequency (more severe than *mia*)     \<10
  *mia2 × oda6*       MIA complex; ODA                  Beat at very low beat frequency (more severe than *mia*)                  10--20
  *mia2 × oda7*       MIA complex; ODA                  Beat at very low beat frequency (more severe than *mia*)                  10--20
  *mia2 × pf4*        MIA complex; PP2A phosphatase     Very short flagella (more severe than *mia*)                              N/A
  *mia2 × pf17*       MIA complex; RS head              Nonmotile (more severe than *mia*)                                        N/A

Typical beat frequencies of cells were measured at room temperature (∼25°C). When cells had no flagella, cells were kept rotating in distilled water for several hours to grow flagella. N/A, not analyzable.

To test whether the MIA complex regulates the function of more than one species of axonemal dynein, we analyzed motility in a series of *C. reinhardtii* double mutants defective in both the MIA complex and selected dynein arms. As expected, doubles between *mia* mutants (*mia1 × mia2*) and I1 dynein--deficient mutants (*mia1 × ida1*, *mia1 × ida2*, *mia1 × bop5*, and *mia2 × bop5*) showed quite similar motility phenotypes to those of *mia* alone (Fig. S4 and [Table 1](#tbl1){ref-type="table"}). These results strongly suggest a functional interaction between the MIA complex and I1 dynein and indicate that the I1 dynein is inactive in the *mia* mutants (see Discussion). The double mutants between the *mia* mutants and *ida4* (lacking dynein a, c, and d), *ida6* (lacking dynein e and having a defect in N-DRC; [@bib62]), and *ida9* (lacking dynein c) all showed more severe motility phenotypes (nearly nonmotile) than either parent ([Table I](#tbl1){ref-type="table"}). Similarly, doubles between the *mia* mutants and *oda* mutants show very low beat frequencies (10--20 Hz), indicating a more severe phenotype than either parent (Fig. S4 and [Table I](#tbl1){ref-type="table"}). These results indicate that the MIA complex operates in the same pathway as I1 dynein but that the MIA complex does not solely regulate the single-headed IDAs or the ODAs.

To determine how the MIA complex contributes to regulation of dynein motor function, we used a sliding disintegration assay to measure microtubule sliding velocities in isolated axonemes ([@bib56]). The microtubule sliding velocities of *mia1* were similar to wild type, although there was some slight variation in the different alleles. In contrast, microtubule sliding velocities of *mia2* were significantly reduced ([Fig. 8](#fig8){ref-type="fig"}). I1 dynein plays a role in control of microtubule sliding by a regulatory pathway that involves the CP, RS, and axonemal kinases and phosphatases ([Fig. 1, A and B](#fig1){ref-type="fig"}; [@bib79]). Dynein-driven microtubule sliding is globally inhibited in isolated, paralyzed axonemes from RS mutants, such as *pf17*, and normal microtubule sliding velocity can be rescued by treating the axonemes with kinase inhibitors ([Fig. 8](#fig8){ref-type="fig"}, KI) including protein kinase inhibitor (PKI; the peptide inhibitor of PKA) and 5,6-dichloro-1-b-[d]{.smallcaps}-ribofuranosylbenzimidazole (DRB; the inhibitor of CK1). Surprisingly, these kinase inhibitors did not rescue the microtubule sliding velocities of *mia2*, whereas these treatments successfully rescued the microtubule sliding of *pf17*. In addition, kinase inhibitor treatment resulted in a decrease in microtubule sliding velocities in *mia1* ([Fig. 8](#fig8){ref-type="fig"}). As discussed in the next section, these results, although revealing the unexpected features of the MIA complex, are consistent with a role for the MIA complex in regulation of dyneins by a pathway that includes the CP/RS/I1 dynein phosphoregulatory mechanism.

![**Regulation of dynein-driven microtubule sliding is disrupted in the *mia* mutants.** ATP- and protease-induced microtubule sliding measurements show the characteristic sliding velocities for wild-type (wt) and *pf17* mutant axonemes. The reduced sliding velocity of *pf17* is rescued to wild-type levels by the addition of a kinase inhibitor (KI). Microtubule sliding velocities of *mia1* (*mia1-1* and *mia1-3*) are similar or only slightly reduced relative to that of wild type but greatly reduced when coupled with the *pf17* mutation (*mia1-1* × *pf17*). Microtubule sliding velocities of *mia2* axonemes are significantly reduced and are not altered by kinase inhibitor treatment (*mia2* + kinase inhibitor). Error bars show standard deviations (*n* = 4--36).](JCB_201211048_Fig8){#fig8}

Discussion
==========

In this study, we addressed the hypothesis that the *MIA1* and *MIA2* genes encode proteins required for regulation of I1 dynein. Consistent with this, these genes encode conserved coiled-coil proteins FAP100 and FAP73, respectively ([Fig. 2, A and B](#fig2){ref-type="fig"}), which interact to form the MIA complex ([Fig. 3 C](#fig3){ref-type="fig"}), a novel regulator of dynein-driven ciliary/flagellar motility. The MIA complex localizes along the entire length of both flagella ([Fig. 6 A](#fig6){ref-type="fig"}), biochemically interacts with I1 dynein components ([Fig. 5 C](#fig5){ref-type="fig"} and Table S1), and is localized near the IC/LC complex--IC138 subcomplex of I1 dynein ([Figs. 6 C](#fig6){ref-type="fig"} and S2, A--C; [@bib2]; [@bib23]). In addition, I1 dynein stability requires assembly of both the MIA complex and ODA ([Fig. 7, A--C](#fig7){ref-type="fig"}), consistent with the presence of a structural link between I1 dynein and ODA ([@bib54]; [@bib9]; [@bib23]). Together, the data indicate a structural and functional interaction between I1 dynein and the MIA complex, which is required for normal ciliary motility. As illustrated in [Fig. 9 (A and B)](#fig9){ref-type="fig"}, we postulate that the MIA complex physically positions the I1 dynein/IC138 ([@bib2]) relative to the predicted position of the axonemal kinases and phosphatases for regulation of IC138 phosphorylation and control of ciliary waveform ([@bib34]; [@bib1]; [@bib78]).

![**Proposed model for the function of the MIA complex in regulation of I1 dynein.** (A) In wild type, the MIA complex is localized in a position to mediate signals to I1 dynein motor complex (orange). Kinases and phosphatases (white in A and red in B), such as CK1, PKA, and PP2A, are predicted to be positioned at the base of the I1 dynein complex, in position to regulate phosphorylation of the IC138 substrate of I1 dynein. (B) In the absence of the MIA complex, these signaling proteins (red) are present but may be mispositioned relative to IC138 and I1 dynein, which are flexible, resulting in hyperphosphorylated IC138 in the *mia* mutants. KIP, kinase--phosphatase complex; p, phosphorylation.](JCB_201211048_Fig9){#fig9}

The MIA complex affects the structure and stability of I1 dynein
----------------------------------------------------------------

Among the primary results of this study was the discovery of the MIA complex. The MIA complex assembles independent of other axonemal structures: the *mia* mutants do not have defects in assembly of other major axonemal structures ([Figs. 4, B and C](#fig4){ref-type="fig"}; and [6 C](#fig6){ref-type="fig"}), and, in turn, the MIA complex assembly is unaffected in mutants of other major axonemal complexes ([Fig. 4 A](#fig4){ref-type="fig"}). Moreover, the kinases (CK1) and phosphatases (PP2A and PP1) involved in the CP--RS--I1 regulatory pathway ([@bib87]; [@bib16]; [@bib13]) are assembled at wild-type levels ([Fig. 5 B](#fig5){ref-type="fig"}). Consistent with our biochemical analyses, [@bib34] found that only an ∼65-kD protein (FAP100), an ∼34-kD protein (FAP73), and an unknown ∼35-kD protein (also missing in *ida1*) are missing or reduced in *mia* mutant axonemes. Although *mia2* only lacks FAP73, *mia1* has defects in both FAP100 and FAP73 in the axoneme, indicating FAP100 is required for ciliary localization of FAP73 but not vice versa ([Figs. 3 A](#fig3){ref-type="fig"} and [4 A](#fig4){ref-type="fig"}).

Cryo-ET of *mia* axonemes identified the putative location of the MIA complex on the outer DMTs. The *mia* mutant axonemes have structural defects in the region between the IC/LC complex of I1 dynein and the N-DRC ([Fig. 6 C](#fig6){ref-type="fig"}, green; and Video 5). The simplest interpretation is that the MIA complex is located adjacent to the IC/LC domain of I1 dynein, an ideal location for regulation of I1 dynein. The reduced densities further distal toward the N-DRC could be downstream structural assembly defects when the MIA complex is missing. Moreover, cryo-ET analyses clearly demonstrate that, in axonemes from the *mia* mutants, I1 dynein is specifically missing along the entire length of DMT1. ODAs are also missing from DMT1 ([@bib26]; [@bib8], [@bib9]; [@bib46]). Thus, one possible explanation is that assembly or stability of I1 dynein is affected by structural interactions with both the ODA and the MIA complex. This hypothesis is supported by analyses of *mia × oda* double mutants, which show a reduced amount of I1 dynein relative to *oda* and *mia* single mutants ([Fig. 7, B and C](#fig7){ref-type="fig"}).

Our results indicate that the MIA complex structurally supports I1 dynein ([Fig. 9, A and B](#fig9){ref-type="fig"}). Consistent with this interpretation, I1 dynein structure is also altered in *mia* axonemes. This is illustrated by the reduced and blurred density of the I1 dynein in *mia* mutants ([Figs. 6 B](#fig6){ref-type="fig"}, [7 A](#fig7){ref-type="fig"}, and S3). Thus, despite the assembly of I1 dynein on DMTs 2--9 in axonemes from *mia* mutants ([Figs. 4, B and C](#fig4){ref-type="fig"}; and [7, B and C](#fig7){ref-type="fig"}), the I1 structure appears more flexible compared with that in wild type ([Fig. 9 B](#fig9){ref-type="fig"}). These observations are also consistent with our recent cryo-ET study revealing that the IC/LC complex appears to be suspended from the A tubule of outer DMTs with only a single, narrow connection (Video 1; [@bib23]). Our observations suggest that the distal connection to the MIA complex is crucial for stable attachment of the I1 dynein IC/LC complex to the axoneme.

The MIA complex may coordinate multiple axonemal pathways for regulation of dyneins
-----------------------------------------------------------------------------------

To test whether the MIA complex functions in the signaling pathways that regulate dynein activity in vivo (e.g., in cooperation with the N-DRC for control of ODA and beat frequency \[[@bib62]\] or with the CP--RS--I1 phosphorylation pathway for control of I1 dynein and waveform \[[@bib79]\]), we isolated and characterized double mutants between the *mia* mutants and previously characterized motility mutants (Fig. S4 and [Table 1](#tbl1){ref-type="table"}). From this analysis, we conclude that the MIA complex does not operate exclusively in any one dynein regulatory pathway. For example, the *mia × pf4* double mutants showed a more severe phenotype than the parent strains alone, suggesting the MIA complex and PP2A function in either separate or only partially overlapping pathways. *mia* × *ida6*, which lacks the MIA complex, several N-DRC components, and IDA e, was nearly nonmotile ([Table 1](#tbl1){ref-type="table"}). Because *mia* mutants and *ida6* alone are both slow swimmers, this result indicates that the MIA complex may function mostly independent of the N-DRC, even though the MIA complex seems to extend between I1 dynein and the N-DRC. This is consistent with the results from [@bib34]: double mutants between *mia* mutants and *pf2* or *pf3* showed severe paralyzed phenotypes. However, we cannot formally exclude a functional interaction between the MIA complex and the N-DRC. In addition, the microtubule sliding velocity in axonemes from *mia* × *pf17* double mutants is slower than in axonemes from *mia* or *pf17* alone ([Fig. 8](#fig8){ref-type="fig"}), suggesting that the MIA complex does not exclusively function in the CP--RS--I1 phosphorylation pathway ([@bib63]; [@bib79]). Thus, the MIA complex may operate in multiple dynein regulatory pathways that affect the activity of both I1 dynein and ODA.

From double mutant analysis, the MIA complex was clearly shown to regulate I1 dynein: doubles between *mia* mutants and the I1 dynein mutants *ida1*, *ida2*, and *bop5* showed a similar motility phenotype to *mia* alone (Fig. S4 and [Table 1](#tbl1){ref-type="table"}). In addition, the *mia* × *bop5* double mutants fail to perform phototaxis similar to the single *mia* mutants ([@bib78]). The *bop5* mutant is particularly informative because it only affects the assembly of the IC138 complex, whereas the remaining I1 dynein subunits assemble as in wild-type axonemes ([@bib2]). Moreover, the *bop5* mutants revealed that the IC138 complex is required for control of flagellar waveform but is not required for phototaxis ([@bib78]). Thus, the MIA complex must have an essential role in phototactic behavior that is independent of the IC138 complex.

We observed reduced beat frequencies (∼40 Hz) and slightly jerky or jerky phenotypes of the *mia* mutants (Fig. S4 and [Table 1](#tbl1){ref-type="table"}; [@bib34]). The simplest explanation for this observation is that the MIA complex either directly or indirectly regulates ODAs because the ODAs control ciliary beat frequency ([@bib6]). We postulate that the MIA complex affects beat frequency and ODA activity via its effects on I1 dynein. Consistent with this hypothesis, defective assembly of I1 dynein results in greatly reduced microtubule sliding velocity in isolated axonemes, suggesting a functional interaction between I1 dynein and ODAs (e.g., [@bib32]; [@bib77]). The functional interaction between I1 dynein and the ODAs could be mediated by the OIDLs observed by cryo-ET ([@bib54]; [@bib9]).

Possible regulatory mechanism of the MIA complex
------------------------------------------------

A primary functional role of the MIA complex appears to be the regulation of I1 dynein. One model, illustrated in [Fig. 9 A](#fig9){ref-type="fig"}, indicates a direct interaction of the I1 IC138 complex ([@bib2]) with the MIA complex and stable positioning of I1 dynein relative to RS1 and presumably relative to the kinase and phosphatase for IC138 ([@bib16]; [@bib13]). In agreement with this model, structural analysis of the *mia* axonemes reveals defective structure just distal to the location of the IC/LC complex ([Figs. 6 C](#fig6){ref-type="fig"} and S2, A--C) and altered structure of I1 dynein on DMTs 2--9 ([Figs. 6 B](#fig6){ref-type="fig"}, [7 A](#fig7){ref-type="fig"}, and S3). In addition, cross-linking analysis reveals interaction between the Mia proteins and IC138 (Table S1).

Diverse evidence has revealed a correlation between the velocity of microtubule sliding and the degree of IC138 phosphorylation: increased IC138 phosphorylation correlates with inhibition of microtubule sliding ([@bib17]; [@bib79]). Thus, the microtubule sliding results of the *mia* mutants were surprising: despite increased phosphorylation of IC138 ([Fig. 5 A](#fig5){ref-type="fig"}) and deficits in structure and assembly of both FAP100 and FAP73 ([Figs. 3 A](#fig3){ref-type="fig"}, [4 A](#fig4){ref-type="fig"}, and [6 C](#fig6){ref-type="fig"}), microtubule sliding velocity was rapid in axonemes from *mia1* alleles ([Fig. 8](#fig8){ref-type="fig"}). In contrast, despite smaller structural defects with only the loss of FAP73 ([Figs. 3 A](#fig3){ref-type="fig"}, [4 A](#fig4){ref-type="fig"}, and [6 C](#fig6){ref-type="fig"}) and increased phosphorylation of IC138, microtubule sliding in *mia2* axonemes was greatly reduced ([Fig. 8](#fig8){ref-type="fig"}). Because the in vivo motility phenotypes of *mia1* and *mia2* are similar, it was surprising to observe the large difference in microtubule sliding between *mia1* and *mia2* axonemes. In addition, we and others ([@bib34]) observed that despite more limited axonemal structural defects, the phosphorylation state of IC138 was more excessive in *mia2* than in *mia1* ([Fig. 5 A](#fig5){ref-type="fig"}). Furthermore, addition of kinase inhibitors to *mia1* axonemes inhibited microtubule sliding, whereas neither DRB nor PKI altered or rescued microtubule sliding in *mia2* axonemes regardless of reduced IC138 phosphorylation ([Fig. 8](#fig8){ref-type="fig"}). These results reveal that the key axonemal phosphatase for IC138 is at least present in *mia* axonemes and can dephosphorylate IC138 in vitro ([Fig. 5 A](#fig5){ref-type="fig"}).

One explanation for these discrepancies is that in axonemes from the *mia* mutants, phosphorylation of IC138 is uncoupled from changes in microtubule sliding. In addition, the *mia* mutants may reveal an important in vivo regulatory mechanism that cannot be studied by the in vitro microtubule sliding assay. For example, changes in IC138 phosphorylation may be very rapid in vivo (e.g., in response to signals from the external environment required for control of waveform) and that assembly of the MIA complex is required to ensure close and efficient interaction between IC138 and axonemal kinases and phosphatases. In contrast, in in vitro assays, changes in phosphorylation may be slow. In any case, further understanding of the apparent discrepancy between live-cell motility and in vitro microtubule sliding in the *mia* mutants will require future analysis of the key, motility-related phosphoresidues in IC138 ([@bib2]; [@bib78]).

Potential functions of the MIA complex in higher organisms
----------------------------------------------------------

Mia proteins are well conserved from *C. reinhardtii* to mammals, suggesting the MIA complex regulates ciliary motility and/or assembly also in higher organisms. The Mia proteins each have two potential homologues in humans; CCDC37 (coiled-coil domain--containing 37) and CCDC38 for FAP100 and CCDC42A and CCDC42B for FAP73 ([Fig. S5, A and B](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp12}). The *CCDC42A* gene is expressed in mouse testes, and mutations in *CCDC42A* result in a failure in flagellar assembly (Yoder, B., personal communication). In addition, *CCDC37* has been recently reported to be one of five hypermethylated and down-regulated genes in human lung squamous cell carcinoma ([@bib40]). Also, *CCDC38* has been recently reported as one of 16 loci that are tightly related to normal pulmonary function ([@bib75]). These studies suggest that potential Mia protein homologues have important functions in mammalian tissues/cells that bear motile cilia.

Materials and methods
=====================

Strains, DNA, and culture conditions
------------------------------------

The strains used in this study are listed in [Table S2](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp13}. The *mia1-2*, *mia1-3*, and *mia1-4* strains were all produced by standard UV mutagenesis and mutant selection as described previously ([@bib30]) and used for the first time in this study. The double mutants were constructed by standard methods ([@bib11]). Cells were cultured in liquid L or Tris-acetate-phosphate medium and grown with aeration on a 14-h/10-h light/dark cycle or under constant illumination. The cDNA sequences of *C. reinhardtii* FAP100 and FAP73 have been deposited in the DNA Data Bank of Japan under accession number AB692780 and AB692781, respectively.

Preparation of flagella and axonemes
------------------------------------

Deflagellation of *C. reinhardtii* cells was induced by treating cells with dibucaine ([@bib81]). Flagella were collected by subsequent centrifugation. To prepare axonemes, flagella were demembranated with 0.2% Nonidet P-40 in HMDEK (30 mM Hepes, 5 mM MgSO~4~, 1 mM DTT, 1 mM EGTA, and 50 mM potassium acetate, pH 7.4) and centrifuged to remove the membrane and matrix fraction. Flagella used for cryo-ET were isolated by the pH shock method, and axonemes were isolated after flagellar demembranation ([@bib82]). Purified axonemes were resuspended in 30 mM Hepes, pH 7.4, 25 mM KCl, 5 mM MgSO~4~, 1 mM EGTA, and 0.1 mM EDTA and processed within 24 h.

SDS-PAGE and immunoblotting
---------------------------

SDS-PAGE and immunoblotting were performed using standard procedures. SDS-PAGE was performed using normal acrylamide gels or 3--5% gradient gels with a 3--8 M urea gradient ([@bib41]; [@bib27]). Gels were stained with Coomassie brilliant blue (CBB) or silver. For immunoblotting, protein samples were separated by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The membranes were blocked with 5% nonfat dry milk and incubated with various primary antibodies. Immunoreactive bands were detected using an HRP-conjugated secondary antibody (Bio-Rad Laboratories) and a 3,3′,5,5′-tetramethylbenzidine peroxidase substrate kit (Vector Laboratories). Antibodies used were anti-DHC1 (I1 dynein HC-α; rabbit; [@bib53]), anti-IC140 (rabbit; [@bib86]), anti-IC138 (rabbit; [@bib20]), anti-IC97 (rabbit; [@bib80]), anti-IC69 (mouse; [@bib36]), antiactin (rabbit; [@bib31]), anti-p28 (rabbit; [@bib42]), anti-RSP1 (rabbit; [@bib37]), anti-FAP100 (rabbit; this study), anti-FAP73 (rabbit; this study), anti-PP2A B subunit (rabbit; [@bib13]), anti-PP2A C subunit (mouse; [@bib88]), anti-PP1 (rabbit; [@bib87]), anti-CK1 (rabbit; [@bib16]), and anti-HA clone 3F10 (rat; Roche).

Polyclonal antibody production
------------------------------

To produce FAP100 and FAP73 polyclonal antibodies, the coding region of *FAP100* or *FAP73* cDNA from wild-type cells was ligated into the BamHI and EcoRI sites of the pCold bacterial expression vector (Takara Bio Inc.). Protein expression was induced by IPTG. The primer pairs used to amplify the coding regions of *FAP100* and *FAP73* cDNA were FAP100-F1, 5′-CT[GGATCC]{.ul}CATATGCCGATTTACGACGAGGCGT-3′; FAP100-R1, 5′-GA[GAATTC]{.ul}AATCATGTCCTGCGCCAGATAC-3′; FAP73-NF1, 5′-CT[GGATCC]{.ul}CATATGGACGAGGAGGGCAGCGCGACTG-3′; and FAP73-NR1, 5′-GA[GAATTC]{.ul}CTCAATCTCCGCGCGCGACGCCAGCGAC-3′. The BamHI and EcoRI sites are underlined. The expressed FAP100 protein contained 6×His tag sequences at its N terminus. The recombinant FAP100 protein was concentrated and collected using a Nickel column and used as the antigen. The expressed FAP73 protein contained 6×His and GST tag sequences at its N terminus. The recombinant FAP73 protein was contained in inclusion bodies, which were isolated and used as the antigen as previously described ([@bib84]). Rabbits were immunized with the antigens, antisera were harvested, and specific antibodies were affinity purified using recombinant proteins on immunoblot membranes.

Phenotypic rescue of *mia* mutants
----------------------------------

For phenotypic rescue, *mia1-2* was transformed with an ∼5.4-kb HindIII--KpnI genomic fragment, which was excised from BAC 16N2 (Clemson University Genomics Institute) and cloned into the pKF19k-2 vector (Takara Bio Inc.). This fragment contained the whole *FAP100* gene. A 3×HA tag was inserted into the DraI site at the C terminus of the *FAP100* gene. The genomic fragment with the HA tag was incorporated in *mia1-2* cells by electroporation as previously described ([@bib69]). For phenotypic rescue of *mia2*, a modified pGenD plasmid vector was used ([@bib14]; [@bib85]). The coding region of *FAP73* was amplified by PCR with the primer pair FAP73-NF1, 5′-CT[GGATCCCATATG]{.ul}GACGAGGAGGGCAGCGCGACTG-3′, and FAP73-NR1, 5′-GA[GAATTC]{.ul}CTCAATCTCCGCGCGCGACGCCAGCGAC-3′, which contained the recognition sites for BamHI, NdeI, and EcoRI (underlined). The NdeI--EcoRI cDNA fragment of *FAP73* was ligated into the pGenD vector and used for transformation of *mia2* cells by electroporation.

Immunoprecipitation
-------------------

Immunoprecipitation under non--cross-linked conditions was performed as described previously ([@bib84]). In brief, the anti-FAP100, anti-FAP73, or anti-HA antibody (Roche) was attached to protein A or G beads and incubated with three times diluted 0.6 M KCl axonemal extracts at 4°C for several hours. The precipitates were washed several times, and the samples were boiled and processed for SDS-PAGE. Immunoprecipitation under cross-linked conditions was performed by the modified method of [@bib66]. Axonemes from *mia1R* and *mia2R* were cross-linked with 5 mM EDC for 1 h at room temperature, boiled in SDS sample buffer containing 1% SDS, diluted 10 times with 1% NP-40 in TBS, and mixed with protein G beads (Santa Cruz Biotechnology, Inc.) with the anti-HA antibody. The mixture was kept rotating overnight at 4°C, washed several times, and subjected to SDS-PAGE. Precipitates were run to the length of ∼10 mm on the gels, stained briefly with CBB, and cut out for the ESI/liquid chromatography/MS/MS analysis. Non--cross-linked *mia1R* and *mia2R* axonemes were processed in the same way as controls. The proteins identified only in EDC cross-linked conditions, but not in non--cross-linked controls, are summarized as the potential Mia complex proteins in Table S1.

Immunofluorescence microscopy
-----------------------------

Immunofluorescence microscopy and nucleoflagellar apparatus preparations were performed as previously described ([@bib67]; [@bib76]). Nucleoflagellar apparatuses were fixed with 2% formaldehyde at room temperature followed by treatment with cold acetone and methanol (−20°C). Fixed samples were stained with an anti-HA antibody (12CA5; Roche) in blocking buffer (10 mM sodium phosphate, pH 7.2, 5% normal goat serum, 5% glycerol, 1% cold fish gelatin, and 0.004% sodium azide) and then with the tetramethyl rhodamine isothiocyanate--labeled anti--mouse IgG antibody (Kirkegaard & Perry Laboratories). Images were acquired on an fluorescence microscope (Axioplan; Carl Zeiss) with a 63×/1.4 NA Plan Apochromat objective lens at room temperature (Carl Zeiss) and recorded with a charge-coupled device camera (CoolSNAP; Roper Scientific).

Microtubule sliding assay
-------------------------

Microtubule sliding assays were performed as described previously ([@bib56]; [@bib16]). Sliding was triggered by the addition of HMDEKP (10 mM Hepes, 5 mM MgSO~4~, 1 mM DTT, 0.5 mM EDTA, 50 mM potassium acetate, and 1% of 20,000 polyethylene glycol) buffer containing 1 mM ATP and 5 µg/ml subtilisin A type VIII protease (Sigma-Aldrich) to axonemes in perfusion chambers. For inhibition experiments, we used 50 µM DRB (Enzo Life Sciences) and 100 nM PKI (Enzo Life Sciences) as kinase inhibitors. Images were recorded with a microscope (Axioplan) equipped with dark-field optics, a 40× Plan Apochromat lens, and a silicon-intensified camera (VE-1000; Dage-MTI). Video images were converted to a digital format using LabVIEW 7.1 software (National Instruments), and sliding velocity was determined manually by measuring microtubule displacement on tracings calibrated with a micrometer.

Beat frequency measurement
--------------------------

Flagellar beat frequency of live *C. reinhardtii* cells was determined using the method of [@bib28] by measuring the vibration frequency of cell bodies with a fast Fourier transform analyzer.

Cryo-ET
-------

Freshly isolated *C. reinhardtii* axonemes were plunge frozen and vitrified on holy grids (R2/2; 200 mesh; Quantifoil Micro Tools) as previously described ([@bib21]). In brief, the grids were glow discharged at −40 mA for 30 s and coated with 10-nm colloidal gold (Sigma-Aldrich). 3 µl of the axoneme sample and 1 µl of 10 times concentrated 10-nm colloidal gold solution were applied to the grid. Then, excess liquid was blotted away, and the grid was plunge frozen in liquid ethane that was cooled by liquid nitrogen. Grids were stored in liquid nitrogen until observed by EM.

Cryo-ET was performed on a transmission electron microscope (Tecnai F30; FEI) operated at 300 keV. Using the microscope control software SerialEM ([@bib50]), tomographic tilt series were collected from −65 to 65° with 1.5--2.5° increments using a −6- or −8-µm defocus to increase the phase contrast. Tilt series were recorded at a nominal magnification of 13,500 using a 2,000 × 2,000--pixel charge-coupled device camera (resulting in a pixel size of 1 nm; Megascan 795; Gatan) and an energy filter (GIF; Gatan) operated in zero-loss mode with 20-eV slit width. The total electron dose used for a tilt series was limited to ∼100 e/Å^2^.

Tomograms showing the 3D structure of *C. reinhardtii* axonemes were reconstructed using the IMOD software package ([@bib39]) with gold fiducial marker alignment and weighted back projection. Some of the tomograms (pWT and *pf9-3/ida1*) were previously used for the analysis of other axonemal complexes ([@bib21], [@bib23]; [@bib46]). Subtomogram averaging of the 96-nm axonemal repeats was performed using the Particle Estimation for Electron Tomography software ([@bib54]) available from the Boulder Laboratory for 3D Electron Microscopy of Cell (Colorado). The University of California, San Francisco, Chimera package ([@bib59]) was used for 3D visualization by isosurface rendering and data analysis. Resolutions of 3D structures obtained by cryo-ET were summarized in [Table S3](http://www.jcb.org/cgi/content/full/jcb.201211048/DC1){#supp14}.

Computational methods
---------------------

Protein domains, motifs, and families were searched using SMART (simple modular architecture research tool; European Molecular Biology Laboratory), Pfam (Wellcome Trust Sanger Institute), and Conserved Domain Database (NCBI) analyses. Coiled-coil regions were predicted by COILS version 2.2. For sequence comparisons, data were aligned using ClustalW, and the output was processed with BoxShade. Images were adjusted for contrast and brightness and assembled using Photoshop (Adobe), Paint (Windows), Illustrator (Adobe), and/or PowerPoint (Microsoft).

Online supplemental material
----------------------------

Fig. S1 shows the immunoblots using the affinity-purified Mia protein antibodies. Fig. S2 shows tomographic slice images obtained by cryo-ET. Fig. S3 shows the localization of the MIA complex and I1 dynein on each doublet. Fig. S4 shows the results of beat frequency analysis. Fig. S5 shows the alignment of *C. reinhardtii* Mia proteins and their potential human homologues. Table S1 lists the potential MIA complex components immunoprecipitated from EDC cross-linked axonemes. Table S2 lists *C. reinhardtii* strains used in this study. Table S3 lists resolutions obtained in cryo-ET. Video 1 shows the reconstructed axonemal repeat of pWT by cryo-ET. Video 2 shows the reconstructed axonemal repeat of *pf9-3*/*ida1*. Video 3 shows the reconstructed axonemal repeat of *mia1-1*. Video 4 shows the reconstructed axonemal repeat of *mia2*. Video 5 shows the reconstructed axonemal repeat of pWT with the potential location of the MIA complex in green. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201211048/DC1>.
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